Key Details
Annual ROE
-39.23%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 01, 2023Recent annual earnings:
Mar 01, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with CCXI included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
ChemoCentryx doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of ChemoCentryx?
- What is the ticker symbol for ChemoCentryx?
- Does ChemoCentryx pay dividends?
- What sector is ChemoCentryx in?
- What industry is ChemoCentryx in?
- What country is ChemoCentryx based in?
- When did ChemoCentryx go public?
- Is ChemoCentryx in the S&P 500?
- Is ChemoCentryx in the NASDAQ 100?
- Is ChemoCentryx in the Dow Jones?
- When was ChemoCentryx's last earnings report?
- When does ChemoCentryx report earnings?
What is the primary business of ChemoCentryx?
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
What is the ticker symbol for ChemoCentryx?
The ticker symbol for ChemoCentryx is NASDAQ:CCXI
Does ChemoCentryx pay dividends?
No, ChemoCentryx does not pay dividends
What sector is ChemoCentryx in?
ChemoCentryx is in the Healthcare sector
What industry is ChemoCentryx in?
ChemoCentryx is in the Biotechnology industry
What country is ChemoCentryx based in?
ChemoCentryx is headquartered in United States
When did ChemoCentryx go public?
ChemoCentryx's initial public offering (IPO) was on 08 February 2012
Is ChemoCentryx in the S&P 500?
No, ChemoCentryx is not included in the S&P 500 index
Is ChemoCentryx in the NASDAQ 100?
No, ChemoCentryx is not included in the NASDAQ 100 index
Is ChemoCentryx in the Dow Jones?
No, ChemoCentryx is not included in the Dow Jones index
When was ChemoCentryx's last earnings report?
ChemoCentryx's most recent earnings report was on 1 March 2023
When does ChemoCentryx report earnings?
The date for ChemoCentryx's next earnings report has not been announced yet